---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-011672"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:13:39.384920+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma's Caldolor expected to qualify for separate Medicare reimbursement under NOPAIN Act from 2025

## Summary
- NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.
- Caldolor (ibuprofen injection) is a non-opioid analgesic indicated for pain management, shown to reduce opioid use.
- Reimbursement applies to products furnished between Jan 1, 2025 and Jan 1, 2028; CMS to issue regs in 2024.
- Caldolor is FDA approved for mild to severe pain in adults and pediatric patients age 6 months+.
- Company expects this will positively impact Caldolor's Medicare reimbursement.

## SEC filing metadata
- accession: 0001628280-23-011672
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/0001628280-23-011672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/cpix-20230414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-011672
- JSON: https://secwatch.observer/filing/0001628280-23-011672.json
- Plain text: https://secwatch.observer/filing/0001628280-23-011672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.